OpenURL Connection Search

Select item for more details and to access through your institution.

Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands.
Published in:
Cancers, 2021, v. 13, n. 20, p. 5077, doi. 10.3390/cancers13205077
By:
- van Breeschoten, Jesper;
- van den Eertwegh, Alfonsus J. M.;
- de Wreede, Liesbeth C.;
- Hilarius, Doranne L.;
- van Zwet, Erik W.;
- Haanen, John B.;
- Blank, Christian U.;
- Aarts, Maureen J. B.;
- van den Berkmortel, Franchette W. P. J.;
- de Groot, Jan Willem B.;
- Hospers, Geke A. P.;
- Kapiteijn, Ellen;
- Piersma, Djura;
- van Rijn, Rozemarijn S.;
- Stevense-den Boer, Marion A. M.;
- van der Veldt, Astrid A. M.;
- Vreugdenhil, Gerard;
- Boers-Sonderen, Marye J.;
- Suijkerbuijk, Karijn P. M.;
- Wouters, Michel W. J. M.
Publication type:
Article
The unfavorable effects of COVID‐19 on Dutch advanced melanoma care.
Published in:
International Journal of Cancer, 2022, v. 150, n. 5, p. 816, doi. 10.1002/ijc.33833
By:
- van Not, Olivier J.;
- van Breeschoten, Jesper;
- van den Eertwegh, Alfonsus J. M.;
- Hilarius, Doranne L.;
- De Meza, Melissa M.;
- Haanen, John B.;
- Blank, Christian U.;
- Aarts, Maureen J. B.;
- van den Berkmortel, Franchette W. P. J.;
- de Groot, Jan Willem B.;
- Hospers, Geke A. P.;
- Ismail, Rawa K.;
- Kapiteijn, Ellen;
- Piersma, Djura;
- van Rijn, Rozemarijn S.;
- Stevense‐den Boer, Marion A. M.;
- van der Veldt, Astrid A. M.;
- Vreugdenhil, Gerard;
- Boers‐Sonderen, Marye J.;
- Blokx, Willeke A. M.
Publication type:
Article
Use of Health-related Quality-of-Life Assessments in Daily Clinical Oncology Nursing Practice A Community Hospital-based Intervention Study.
Published in:
Cancer (0008543X), 2008, v. 113, n. 3, p. 628, doi. 10.1002/cncr.23623
By:
- Hilarius, Doranne L.;
- Kloeg, Paul H.;
- Gundy, Chad M.;
- Aaronson, Neil K.
Publication type:
Article
Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
Published in:
2012
By:
- Hilarius DL;
- Kloeg PH;
- van der Wall E;
- van den Heuvel JJ;
- Gundy CM;
- Aaronson NK;
- Hilarius, Doranne L;
- Kloeg, Paul H;
- van der Wall, Elsken;
- van den Heuvel, Joris J G;
- Gundy, Chad M;
- Aaronson, Neil K
Publication type:
journal article
Real‐world outcomes of advanced melanoma patients not represented in phase III trials.
Published in:
International Journal of Cancer, 2020, v. 147, n. 12, p. 3461, doi. 10.1002/ijc.33162
By:
- Zeijl, Michiel C. T.;
- Ismail, Rawa K.;
- Wreede, Liesbeth C.;
- Eertwegh, Alfonsus J. M.;
- Boer, Anthonius;
- Dartel, Maaike;
- Hilarius, Doranne L.;
- Aarts, Maureen J. B.;
- Berkmortel, Franchette W. P. J.;
- Boers‐Sonderen, Marye J.;
- Groot, Jan‐Willem B.;
- Hospers, Geke A. P.;
- Kapiteijn, Ellen;
- Piersma, Djura;
- Rijn, Rozemarijn S.;
- Suijkerbuijk, Karijn P. M.;
- ten Tije, Albert J.;
- Veldt, Astrid A. M.;
- Vreugdenhil, Gerard;
- Haanen, John B. A. G.
Publication type:
Article
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
Published in:
2022
By:
- van Breeschoten, Jesper;
- Wouters, Michel W. J. M.;
- Hilarius, Doranne L.;
- Haanen, John B.;
- Blank, Christian U.;
- Aarts, Maureen J. B.;
- van den Berkmortel, Franchette W. P. J.;
- de Groot, Jan-Willem B.;
- Hospers, Geke A. P.;
- Kapiteijn, Ellen;
- Piersma, Djura;
- van Rijn, Roos S.;
- Suijkerbuijk, Karijn P. M.;
- Blokx, Willeke A. M.;
- Tije, Bert-Jan J. ten;
- Veldt, Astrid A. M. van der;
- Vreugdenhil, Art;
- Boers-Sonderen, Marye J.;
- van den Eertwegh, Alfonsus J. M.
Publication type:
corrected article
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
Published in:
2021
By:
- van Breeschoten, Jesper;
- Wouters, Michel W. J. M.;
- Hilarius, Doranne L.;
- Haanen, John B.;
- Blank, Christian U.;
- Aarts, Maureen J. B.;
- van den Berkmortel, Franchette W. P. J.;
- de Groot, Jan-Willem B.;
- Hospers, Geke A. P.;
- Kapiteijn, Ellen;
- Piersma, Djura;
- van Rijn, Roos S.;
- Suijkerbuijk, Karijn P. M.;
- Blokx, Willeke A. M.;
- ten Tije, Bert-Jan J.;
- van der Veldt, Astrid A. M.;
- Vreugdenhil, Art;
- Boers-Sonderen, Marye J.;
- van den Eertwegh, Alfonsus J. M.
Publication type:
corrected article
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
Published in:
2021
By:
- van Breeschoten, Jesper;
- Wouters, Michel W. J. M.;
- Hilarius, Doranne L.;
- Haanen, John B.;
- Blank, Christian U.;
- Aarts, Maureen J. B.;
- van den Berkmortel, Franchette W. P. J.;
- de Groot, Jan-Willem B.;
- Hospers, Geke A. P.;
- Kapiteijn, Ellen;
- Piersma, Djura;
- van Rijn, Roos S.;
- Suijkerbuijk, Karijn P. M.;
- Blokx, Willeke A. M.;
- Tije, Bert-Jan J. ten;
- Veldt, Astrid A. M. van der;
- Vreugdenhil, Art;
- Boers-Sonderen, Marye J.;
- van den Eertwegh, Alfonsus J. M.
Publication type:
journal article

Found: 8

Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands.

The unfavorable effects of COVID‐19 on Dutch advanced melanoma care.

Use of Health-related Quality-of-Life Assessments in Daily Clinical Oncology Nursing Practice A Community Hospital-based Intervention Study.

Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.

Real‐world outcomes of advanced melanoma patients not represented in phase III trials.

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysis.

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysis.

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysis.